Skip to main content

Table 2 IC50 average parameters in nM for wild type (I356) and mutant (356T) P. falciparum isolates from West Africa and Central Africa for piperaquine (PPQ), quinine (QN), mefloquine (MQ), chloroquine (CQ), lumefantrine (LMF), desethylamodiaquine (DQ), pyronaridine (PND), dihydroartemisinin (DHA) and artesunate (AS)

From: Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates

Drugs West Africa Central Africa
Wild type I356 Mutant 356T p value Wild type I356 Mutant 356T p value
Median (no) Min-Max Median (no) Min-Max Median (no) Min–Max Median (no) Min–Max
PPQ 22.2 (49) 6.8–76.3 19.9 (66) 1.2–544 0.32 24.5 (36) 4.1–79 21.4 (70) 0.67–96.3 0.4
QN 69.1 (49) 11.7–906.3 162.6 (68) 6.2–590.5 0.001 98.2 (36) 17.6–365.2 183.4 (73) 28.9–538.4 0.02
MQ 30.4 (49) 2.9–89.8 22.4 (67) 0.8–100.6 0.01 33.3 (38) 0.7–97.9 21.5 (72) 0.62–133.9 0.04
CQ 37.4 (49) 6.2–283.2 26.5 (68) 5.5–359.5 0.1 42.8 (39) 4.1–474.2 26.9 (73) 5.79–325 0.01
LMF 3.0 (49) 0.5–61.54 4.0 (68) 0.6–18.2 0.6 2.8 (40) 0.6–15.5 3.6 (73) 0.55–22.4 0.5
DQ 19.2 (49) 3.4–169.2 27.1 (68) 2.5–185.1 0.07 22.8 (40) 5.1–152.8 20.8 (73) 4.7–152.9 0.4
PND 8.8 (48) 1.2–50.1 14.5 (66) 0.7–119.3 0.005 11.1 (38) 3.9–41 12.3 (67) 0.2–47.9 0.8
DHA 2.9 (49) 0.4–8.3 3.1 (68) 0.2–12.8 0.9 3.5 (40) 0.7–7.7 2.1 (73) 0.47–11.1 0.08
AS 1.8 (49) 0.4–15.48 1.8 (67) 0.2–9.8 0.6 2.5 (39 0.6–5.7 1.7 (71) 0.29–30.2 0.05
  1. West Africa: Benin, Burkina Faso, the Gambia, Ghana, Guinea, Ivory Coast, Niger, Mali, Nigeria and Togo
  2. Central Africa: Cameroon, Central African Republic, Chad, Gabon and Republic of Congo
  3. Italic p values refers to significant difference (p < 0.05)